Industry News
Biotechnology Industry News
Kezar scarred as midphase autoimmune blowup raises doubts about pipeline-in-a-drug vision
Kezar scarred as midphase autoimmune blowup raises doubts about pipeline-in-a-drug vision ntaylor Wed, 05/04/2022 - 09:28
Catalio reloads with $381M after financing Octant, Pheast
Catalio reloads with $381M after financing Octant, Pheast aarmstrong Wed, 05/04/2022 - 09:23
Biogen shoves Aduhelm to the side. It’s time for lecanemab
Biogen shoves Aduhelm to the side. It's time for lecanemab aarmstrong Wed, 05/04/2022 - 08:22
Chasing Bristol Myers and Pfizer, Connect fails phase 2 ulcerative colitis trial but spies path forward
Chasing Bristol Myers and Pfizer, Connect fails phase 2 ulcerative colitis trial but spies path forward ntaylor Wed, 05/04/2022 - 07:54
BMS, Merck KGaA push protein degrader ambitions with $2.3B Amphista partnerships
BMS, Merck KGaA push protein degrader ambitions with $2.3B Amphista partnerships mbayer Tue, 05/03/2022 - 18:38
Record-breaking 2021 revenue shows there’s more to Swiss biotech sector than Roche, Novartis
Record-breaking 2021 revenue shows there's more to Swiss biotech sector than Roche, Novartis mbayer Tue, 05/03/2022 - 14:22
Another Pfizer gene therapy is free of FDA hold, but delay continues
Another Pfizer gene therapy is free of FDA hold, but delay continues gmasson Tue, 05/03/2022 - 11:00
Bad news from FDA prompts Spero to lay off 75% of staff, drop UTI drug
Bad news from FDA prompts Spero to lay off 75% of staff, drop UTI drug jwaldron Tue, 05/03/2022 - 10:40
After a dismal last year, Sesen Bio grasps for alternatives to stay afloat
After a dismal last year, Sesen Bio grasps for alternatives to stay afloat mbayer Tue, 05/03/2022 - 10:18
Sierra wanted a partnership, but GSK wanted the store: How the $1.9B buyout came to be
Sierra wanted a partnership, but GSK wanted the store: How the $1.9B buyout came to be aarmstrong Tue, 05/03/2022 - 10:04
Early clinical data on psilocybin in anorexia point Compass to potential new opportunity
Early clinical data on psilocybin in anorexia point Compass to potential new opportunity ntaylor Tue, 05/03/2022 - 08:34
Dianthus to follow ‘north star’ on mission to reduce autoimmune injections with $100M funding
Dianthus to follow 'north star' on mission to reduce autoimmune injections with $100M funding jwaldron Tue, 05/03/2022 - 08:19
Tackling toxicity, Tubulis lands $63M to advance ADC pipeline spearheaded by Adcetris rival
Tackling toxicity, Tubulis lands $63M to advance ADC pipeline spearheaded by Adcetris rival ntaylor Tue, 05/03/2022 - 03:10
As expected, FDA spikes down Axsome migraine med, but issues are ‘addressable’
As expected, FDA spikes down Axsome migraine med, but issues are 'addressable' mbayer Mon, 05/02/2022 - 16:25
All Takeda wants for its billion-dollar gene therapy spending spree is functional cures
All Takeda wants for its billion-dollar gene therapy spending spree is functional cures aarmstrong Mon, 05/02/2022 - 15:36
Biogen takes another dip into Scribe gene therapy collab with another disease target
Biogen takes another dip into Scribe gene therapy collab with another disease target mbayer Mon, 05/02/2022 - 13:30
Patient Square Capital invests $300M to support ‘golden age of therapeutics’ with Enavate Sciences
Patient Square Capital invests $300M to support 'golden age of therapeutics' with Enavate Sciences gmasson Mon, 05/02/2022 - 11:52
Unwelcome surprise for Vertex as FDA slaps hold on phase 1/2 diabetes cell therapy study
Unwelcome surprise for Vertex as FDA slaps hold on phase 1/2 diabetes cell therapy study aarmstrong Mon, 05/02/2022 - 10:23
Eyelid mites no match for Tarsus eye drop, as phase 3 data spurs drive to FDA
Eyelid mites no match for Tarsus eye drop, as phase 3 data spurs drive to FDA mbayer Mon, 05/02/2022 - 10:16
Eyelid mites no match for Tarsus eye drop, as phase 3 data spur drive to FDA
Eyelid mites no match for Tarsus eye drop, as phase 3 data spur drive to FDA mbayer Mon, 05/02/2022 - 10:16